Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
about
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.The transcriptome of CDK4/6 inhibitionCDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.The role of abemaciclib in treatment of advanced breast cancer.ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
P2860
Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Biological specificity of CDK4 ...... composite response signature.
@en
type
label
Biological specificity of CDK4 ...... composite response signature.
@en
prefLabel
Biological specificity of CDK4 ...... composite response signature.
@en
P2093
P2860
P356
P1433
P1476
Biological specificity of CDK4 ...... composite response signature.
@en
P2093
Agnieszka K Witkiewicz
Erik S Knudsen
Jack Hutcheson
Paris Vail
P2860
P304
43678-43691
P356
10.18632/ONCOTARGET.18435
P407
P577
2017-06-10T00:00:00Z